乙型肝炎表面抗原阴性受者使用乙型肝炎表面抗原阳性肝脏同种异体移植物后的结果。

IF 4.7 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Liver Transplantation Pub Date : 2025-07-01 Epub Date: 2024-11-08 DOI:10.1097/LVT.0000000000000533

Adam S Myer, Drake A Seccurro, Kenneth E Sherman, Yeshika Sharma

{"title":"乙型肝炎表面抗原阴性受者使用乙型肝炎表面抗原阳性肝脏同种异体移植物后的结果。","authors":"Adam S Myer, Drake A Seccurro, Kenneth E Sherman, Yeshika Sharma","doi":"10.1097/LVT.0000000000000533","DOIUrl":null,"url":null,"abstract":"The use of positive HBsAg (HBsAg+) liver allografts has been increasing globally and is gaining wider acceptance within the United States. However, most of the data supporting the use of HBsAg+ organs has been in the setting of recipients with chronic hepatitis B. We aim to describe our institutional experience using HBsAg+ liver donors in HBsAg-negative recipients through case series. Between 2019 and 2021, 10 HBsAg-negative recipients received an HBsAg+ liver transplant. Kaplan-Meier survival analysis showed no difference in survival when compared to all other liver transplants performed at the institution during the same period ( p = 0.5, HR = 1.6, CI = 0.4-6.5). Based on these findings, the use of HBsAg+ liver donors appears to be safe; however, continued follow-up is required to understand further risks associated with the use of HBsAg+ liver allografts.","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":" ","pages":"870-876"},"PeriodicalIF":4.7000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcomes following the use of HBsAg-positive liver allografts in HBsAg-negative recipients.\",\"authors\":\"Adam S Myer, Drake A Seccurro, Kenneth E Sherman, Yeshika Sharma\",\"doi\":\"10.1097/LVT.0000000000000533\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The use of positive HBsAg (HBsAg+) liver allografts has been increasing globally and is gaining wider acceptance within the United States. However, most of the data supporting the use of HBsAg+ organs has been in the setting of recipients with chronic hepatitis B. We aim to describe our institutional experience using HBsAg+ liver donors in HBsAg-negative recipients through case series. Between 2019 and 2021, 10 HBsAg-negative recipients received an HBsAg+ liver transplant. Kaplan-Meier survival analysis showed no difference in survival when compared to all other liver transplants performed at the institution during the same period ( p = 0.5, HR = 1.6, CI = 0.4-6.5). Based on these findings, the use of HBsAg+ liver donors appears to be safe; however, continued follow-up is required to understand further risks associated with the use of HBsAg+ liver allografts.\",\"PeriodicalId\":18072,\"journal\":{\"name\":\"Liver Transplantation\",\"volume\":\" \",\"pages\":\"870-876\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Liver Transplantation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/LVT.0000000000000533\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/LVT.0000000000000533","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

全球范围内使用乙肝表面抗原（HBsAg+）阳性肝脏同种异体移植的情况越来越多，在美国也越来越被广泛接受。然而，大多数支持使用 HBsAg+ 器官的数据都是在慢性乙型肝炎受者的情况下获得的。我们旨在通过病例系列描述我们的机构在 HBsAg 阴性受者中使用 HBsAg+ 肝脏供体的经验。2019 年至 2021 年间，10 名 HBsAg 阴性受者接受了 HBsAg+ 肝移植。Kaplan-Meier生存率分析表明，与同期在该机构进行的所有其他肝移植相比，生存率没有差异（P=0.5，HR=1.6，CI=0.4-6.5）。根据这些研究结果，使用HBsAg+肝脏供体似乎是安全的；但是，要了解使用HBsAg+肝脏同种异体移植的进一步风险，还需要继续跟踪。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Outcomes following the use of HBsAg-positive liver allografts in HBsAg-negative recipients.

The use of positive HBsAg (HBsAg+) liver allografts has been increasing globally and is gaining wider acceptance within the United States. However, most of the data supporting the use of HBsAg+ organs has been in the setting of recipients with chronic hepatitis B. We aim to describe our institutional experience using HBsAg+ liver donors in HBsAg-negative recipients through case series. Between 2019 and 2021, 10 HBsAg-negative recipients received an HBsAg+ liver transplant. Kaplan-Meier survival analysis showed no difference in survival when compared to all other liver transplants performed at the institution during the same period ( p = 0.5, HR = 1.6, CI = 0.4-6.5). Based on these findings, the use of HBsAg+ liver donors appears to be safe; however, continued follow-up is required to understand further risks associated with the use of HBsAg+ liver allografts.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Liver Transplantation 医学-外科

CiteScore

7.40

自引率

6.50%

发文量

254

审稿时长

3-8 weeks

期刊介绍： Since the first application of liver transplantation in a clinical situation was reported more than twenty years ago, there has been a great deal of growth in this field and more is anticipated. As an official publication of the AASLD, Liver Transplantation delivers current, peer-reviewed articles on liver transplantation, liver surgery, and chronic liver disease — the information necessary to keep abreast of this evolving specialty.